Join our daily newsletter At The Bell to receive exclusive market insights
- Nutritional Growth Solutions (NGS) will carry out a clinical trial of Healthy Height on kids with ADHD at the Schneider Children’s Medical Centre in Israel
- The Healthy Height nutritional treatment is already proven to improve the height and weight in short and lean kids aged three to nine by up to 34 per cent
- This new trial will test whether using NGS’s Healthy Height increases growth in children treating ADHD using stimulant medication
- Studies show kids with ADHD who are being treated with these stimulants may suffer a reduction in height growth
- NGS shares are trading steady at 27 cents per share at 1:04 pm AEST
Nutritional Growth Solutions (NGS) will carry out a clinical trial of Healthy Height on kids with ADHD at the Schneider Children’s Medical Centre in Israel.
The Healthy Height nutritional treatment has already been proven to improve the height and weight in short and lean kids aged three to nine by up to 34 per cent.
NGS now wants to test whether it can help children with ADHD who are on stimulants, as studies show these kids may suffer reduced height gains.
The company said it had signed an agreement with Schneider, where Healthy Height was first created, to test between 70 and 140 children.
All of the trial participants will be aged under 10, diagnosed with ADHD and being treated using stimulant medication.
Half of them will supplement their diet with the Healthy Height formula, while the other 50 per cent will take a placebo product.
Commenting on the trial, NGS CEO and Managing Director Liron Fendell said he was hopeful Healthy Heights would help these children.
“ADHD is a prevalent disorder globally with treatment’s adverse side effects including decreased appetite,” Mr Fendell said.
“In the US, insurance coverage decisions by commercial insurance and government payers are tied to medical necessity and discreet diagnoses.
“If the trial provides clear evidence that Healthy Height supports children with
an ADHD diagnosis who have been prescribed meds achieve normal growth and counteract the negative effects of the drugs, we believe the payers will be more likely to cover Healthy Height alongside an ADHD diagnosis.”
Shares in Nutritional Growth Solutions were trading steady at 27 cents each at 1:04 pm AEST.
